EP1595878A1 - Derives d'indole destines a l'induction d'apoptose - Google Patents

Derives d'indole destines a l'induction d'apoptose Download PDF

Info

Publication number
EP1595878A1
EP1595878A1 EP04011598A EP04011598A EP1595878A1 EP 1595878 A1 EP1595878 A1 EP 1595878A1 EP 04011598 A EP04011598 A EP 04011598A EP 04011598 A EP04011598 A EP 04011598A EP 1595878 A1 EP1595878 A1 EP 1595878A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
substituted
unsubstituted
indol
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04011598A
Other languages
German (de)
English (en)
Inventor
Matthias Dr. Gerlach
Tilmann Dr. Schuster
Peter Dr. Emig
Peter Schmidt
Silke Dr. Baasner
Günther Dr. Eckhard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris AG filed Critical Zentaris AG
Priority to EP04011598A priority Critical patent/EP1595878A1/fr
Priority to KR1020057023347A priority patent/KR101132599B1/ko
Priority to NZ543853A priority patent/NZ543853A/en
Priority to PCT/EP2004/005593 priority patent/WO2004108702A1/fr
Priority to YUP-2005/0901A priority patent/RS20050901A/sr
Priority to MXPA05013121A priority patent/MXPA05013121A/es
Priority to JP2006508197A priority patent/JP4878285B2/ja
Priority to RU2006100022/04A priority patent/RU2327696C2/ru
Priority to EP04734662A priority patent/EP1641777A1/fr
Priority to CA2526663A priority patent/CA2526663C/fr
Priority to BRPI0410998-8A priority patent/BRPI0410998A/pt
Priority to AU2004245198A priority patent/AU2004245198B2/en
Priority to CN2004800192716A priority patent/CN1816543B/zh
Priority to TW093115555A priority patent/TWI344462B/zh
Priority to US10/858,751 priority patent/US7205299B2/en
Priority to ARP040101959A priority patent/AR044628A1/es
Publication of EP1595878A1 publication Critical patent/EP1595878A1/fr
Priority to IL172130A priority patent/IL172130A/en
Priority to NO20060045A priority patent/NO20060045L/no
Priority to HK06113749.1A priority patent/HK1093065A1/xx
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present invention relates to novel indole derivatives having improved biological activity, improved tolerability and improved oral Bioavailability, used as a drug to treat tumors, especially for drug resistance to other drugs and metastatic Carcinoma be used.
  • Tumor drugs work through mechanisms such as the blockade of the cell division mechanism the cell, stopping the supply of the tumor with Nutrients and oxygen (antiangiogenesis), the prevention of metastasis, preventing the receipt and transmission of growth signals to the tumor cell or the displacement of the tumor cell in the programmed cell death (apoptosis).
  • Indole derivatives find pharmacodynamically active compounds and as synthetic building blocks in pharmaceutical chemistry a diverse Use.
  • the applicant's WO 02/10152 A2 already describes another Class of indole derivatives for the treatment of tumors.
  • the active ingredient was N- (2-methyl-6-quinolyl) - [1- (4-chlorobenzyl) -indol-3-yl] -glyoxylic acid amide on its anti-proliferative effect on various tumor cell lines tested.
  • a problem underlying the invention is now cytotoxic To provide substances with combined mechanisms of action, for the treatment of a variety of tumors, especially in drug resistance against other medicines and metastatic carcinomas suitable.
  • R is an unsubstituted or substituted 2-, 3-, 4-, 5- or 6-pyridyl group and R1-R6 og has meaning, R7 in this case not for an acetyl radical or a tert -Butyloxycarbonyl distr stand.
  • the present invention is a further development of the invention, which is described in WO 02/10152. It was found that the indole derivatives when replacing the 2-methyl-6-quinolyl group with unsubstituted or substituted 2-, 3-, 6-, 7- and 8-pyridopyrazinyl, unsubstituted or substituted 3-, 4-, 5-, 6- and 7-indazolyl, an improved antiproliferative activity show different tumor cell lines.
  • the compounds of the invention an improved water solubility and thus also an improved oral Possess bioavailability.
  • the possibility a lower, longer lasting and better tolerated medication Antitumor effect can be opened than with the classical cytostatics. Especially is said to be the adverse resistance, as many antitumor agents is known to be bypassed.
  • the with the indole derivatives according to the invention The effect enhancement achieved is intended to make drug consumption more effective. In addition, it should be possible to switch to treatment-resistant cases expand.
  • R1 4-chlorobenzyl, R2-R6 hydrogen, R heterocycle and R7 is alkylcarbonyl or alkoxycarbonyl.
  • heterocycle is meant by the Term, unless explicitly stated above, pyrrole, furan, thiophene, pyrazole, Thiazole, indole, oxazole, imidazole, isothiazole, isoxazole, 1,2,3-triazole, 1,2,4-triazole, 1,2,4, oxadiazole, 1,3,4-oxadiazole, 1,2,5-thiadiazole, 1,3,4-thiadiazole, tetrazole, Pyridine, pyrimidine, pyridazine, pyrazine, benzofuran, indazole, carbazole, benzoxazole, Benzimidazole, benzothiazole, benzotriazole, quinoline, cinnoline, quinoxaline, quinazoline, Phthalazine, pyridopyrazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-
  • alkyl for the purposes of this invention comprises acyclic saturated or unsaturated hydrocarbons, which may be straight-chain or branched.
  • substituted in the context of this invention, unless explicitly defined above, means the substitution of a hydrogen radical by F, Cl, Br, I, CN, NH 2 , NH-alkyl, NH-cycloalkyl , OH, O-alkyl, where multiply substituted radicals are understood as meaning those which are monosubstituted, for example mono- or trisubstituted, either on different or on the same atoms, for example three times on the same carbon atom as in the case of -CF 3 , -CH 2 CF 3 or at different positions as in the case of -CH (OH) -CH 2 -CH 2 -CHCl 2 .
  • the multiple substitution can be with the same or different substituent.
  • alkyl-aryl means (C 1 -C 6 ) -alkyl- (C 6 -C 14 ) -aryl, and preferably (C 1 -C 6 ) -alkyl-C 6 -aryl.
  • alkyl-aryl and to “cycloalkyl” is meant in the sense of this invention insofar not explicitly mentioned above "mono- or polysubstituted" the one or more, for example two-, three- or four-fold substitution of one or more Hydrogen atoms of the ring system by F, Cl, Br, I, CN, NH 2 , NH-alkyl, OH, O-alkyl, CF 3 , alkyl, (C 6 -C 10 ) -aryl, (C 6 -C 10 ) - Aryl- (C 1 -C 6 ) -alkyl and / or heterocyclyl, on one or optionally different atoms (where a substituent may be substituted in turn).
  • the multiple substitution is carried out with the same or different substituents.
  • “monosubstituted or polysubstituted” is taken to mean single or multiple, for example, two-, three- or four-fold substitution of one or more hydrogen atoms of the ring system by F, Cl, Br , I, nitro, amino, C 1 -C 6 -alkyl, preferably methyl, mono- (C 1 -C 6 ) -alkylamino, di- (C 1 -C 6 ) -alkylamino, hydroxy, C 1 -C 6 - Alkoxy, benzyloxy, carboxy, (C 1 -C 6 ) -alkoxycarbonyl, (C 1 -C 6 ) -alkoxycarbonylamino or mono- or polysubstituted with fluorine-substituted (C 1 -C 6 ) -alkyl, preferably trifluoromethyl, (C 6 - C 10 )
  • the compounds of the invention of the general Formula I have at least one asymmetric center, they can in the form of their Racemates, in the form of pure enantiomers and / or diastereomers or in Form of mixtures of these enantiomers and / or diastereomers.
  • the mixtures may be in any mixing ratio of the stereoisomers available. If possible, the compounds of the invention in Form of tautomers are present.
  • the compounds of the invention according to the general formula I which one or more chiral centers and which occur as racemates, according to methods known per se in to separate their optical isomers, ie enantiomers or diastereomers.
  • the Separation may be by column separation on chiral phases or by recrystallization from an optically active solvent or using a optically active acid or base or by derivatization with an optical active reagent, such as an optically active alcohol, and subsequently Cleavage of the rest done.
  • the compounds of the general formula I according to the invention if they contain a sufficiently acidic group such as, for example, the carboxy group, can be converted into their physiologically tolerated salts with inorganic and / or organic bases.
  • Suitable inorganic bases are, for example, sodium hydroxide, potassium hydroxide, calcium hydroxide, as organic bases ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dibenzylethylenediamine and lysine.
  • the stoichiometry of the formed salts of the compounds according to the invention can be integer or non-integer multiples of one.
  • the compounds of the general formula I according to the invention if they have a sufficiently basic group, such as, for example, a secondary or tertiary amine, can be salified with inorganic and organic acids.
  • the pharmaceutically acceptable salts of the compounds of general structure I according to the invention are hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, p-toluenesulfonic, carbonic, formic, acetic, trifluoroacetic, oxalic, malonic, maleic, succinic, tartaric, racemic, malic , Embonic acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid or aspartic acid.
  • the salts formed include hydrochlorides, hydrobromides, sulfates, phosphates, methanesulfonates, sulfoacetic acid, tosylates, carbonates, bicarbonates, formates, acetates, triflates, oxalates, malonates, maleates, succinates, tartrates, malates, embonates, mandelates, fumarates , Lactates, citrates and glutaminates.
  • the stoichiometry of the formed salts of the compounds according to the invention can be integer or non-integer multiples of one.
  • solvates and in particular hydrates of the compounds I according to the invention which are eg. B. can be obtained by crystallization from a solvent or aqueous solution.
  • solvate or water molecules can combine with the compounds according to the invention to give solvates and hydrates.
  • Both the compounds of formula I and their salts are biologically active.
  • the compounds of formula I can be administered in free form or as salts with physiologically acceptable acids or bases.
  • the administration of the compounds of the general formula can oral, rectal, buccal (e.g., sublingual), parenteral (e.g., subcutaneous, intramuscular, intradermally or intravenously), topically or transdermally.
  • buccal e.g., sublingual
  • parenteral e.g., subcutaneous, intramuscular, intradermally or intravenously
  • the invention relates to medicaments containing at least one of the compounds of the formula I or their salts with physiological compatible inorganic or organic acids and optionally pharmaceutically usable carrier and / or diluents or auxiliaries.
  • These medicines are used to treat tumors, in particular for the treatment of tumor diseases with drug resistance against other drugs and / or tumors with metastatic Carcinoma used.
  • Suitable administration forms are tablets, dragees, Capsules, solutions for infusion or ampoules, suppositories, patches, inhalable powder preparations, suspensions, creams and ointments.
  • the compounds of the invention may also be in a microparticulate z.
  • the compounds (1), (4) and (11) are compounds, wherein the R7 is hydrogen.
  • Compounds (2), (3), (5) and (6) to (8) contain as group R7 an alkylcarbonyl or alkoxycarbonyl group.
  • the starting compounds II , III and IV are either commercially available or can be prepared by methods known per se.
  • the educts II , III and IV are valuable intermediates for the preparation of the indole derivatives of the formula I according to the invention.
  • reaction temperature and duration are optionally used solvents and auxiliaries and applicable reaction parameters such as reaction temperature and duration known to the skilled person due to his expertise.
  • the reaction mixture is poured into water, extracted with ethyl acetate, the organic phase washed with saturated sodium chloride solution and dried over anhydrous MgSO4. Evaporation of the solvent gives a crude product, which is purified by column chromatography (n-heptane / acetone 2/1) to give 3 .
  • 3 still shows small impurities in thin layer chromatography, which can be removed by stirring the crude 3 with acetone for 1 h. The filtration gives 3 as pale yellow crystals.
  • Example 17 Antiproliferative activity on various tumor cell lines
  • Substances 1, 2, 4, 9 , 11 , 12 , 13 and 15 were tested for their anti-proliferative activity in a proliferation test on established tumor cell lines (DA Scuderio et al., Cancer Res. 1988, 48, 4827-4833).
  • the test used determines the cellular dehydrogenase activity and allows determination of cell vitality and, indirectly, cell number.
  • the cell lines used are the human cervical carcinoma cell line KB / HeLa (ATCC CCL17), the ovarian adenocarcinoma cell line SKOV-3 (ATCC HTB77), the human glioblastoma cell line SF-268 (NCI 503138) and the lung carcinoma cell line NCI-H460 ( NCI 503473).
  • the results show a very potent inhibition of the proliferation of selected tumor cell lines by the embodiments 1, 2, 4 and 11 .
  • substances 1, 2, 4 and 11 were compared multi-drug resistant cell lines compared to the non-resistant wild-type cell lines examined.
  • the investigated cell lines are the murine L1210, the acute one myeloid leukemia cell line LT12 and the resistant L1210 / mdr lines and LT12 / mdr.
  • murine P388 cell line methyl-cholanthreneinduced lymphoid neoplasm
  • doxorubicin-resistant P388 as test systems used.
  • the substances 1, 2, 4 and 11 show a very potent inhibitory effect on all tested cell lines while in the classical tubulin-inhibitory effective Substances such as paclitaxel or vincristine further in the topoisomerase II inhibitors (Doxorubicin, mitoxantrone, etoposide) one at least strong diminished effect on the MDR1 resistant cell lines can be seen.
  • paclitaxel or vincristine further in the topoisomerase II inhibitors (Doxorubicin, mitoxantrone, etoposide) one at least strong diminished effect on the MDR1 resistant cell lines can be seen.
  • Substances 1, 4, 9, 11, 12, 13 and 15 were tested in an in vitro assay for inhibition of bovine tubulin polymerization (DM Bollag et al., Cancer Res. 1995, 55, 2325-2333). In this test, purified tubulin is used through cycles of polymerization and depolymerization, which is brought to polymerization by addition of GTP and heating. Table 3 shows the EC 50 values of polymerization inhibition of tubulin with 30% associated proteins (MAPs). Inhibition of tubulin polymerization. Average of two independent experiments.
  • Substance 1 was tested in two different in vitro tests for inhibition of topoisomerase II.
  • kDNA is treated with human DNA topoisomerase II in the absence or presence of the test compounds.
  • the testing of the compound 1 of the invention was carried out in this case at three different concentrations (100, 31.6 and 10 ⁇ M).
  • m-Amsa m-amsacrine
  • paclitaxel Taxol
  • vincristine at a respective concentration of 100 ⁇ M.
  • reaction mixtures are placed in the preheated to 37 ° C heating block and incubated at 37 ° C for 10 min. The incubation is stopped after addition of 4 .mu.L 5 ⁇ stop buffer and subsequently the substance is extracted with CIA. Thereafter, 20 ⁇ L of the supernatant are applied to a 1% agarose gel with 0.25 ⁇ g / mL ethidium bromide and separated at 100 V for 1 h. Finally, the gel is photographed under UV excitation (see Figure 1). The quantification of the inhibition of the decationation of kDNA is carried out with the GelPro®Analyzer software (see FIG.
  • the cell cycle involves the development of the cell from a cell generation to next.
  • the cell During the resting phase (G0) and presynthetic phase (G1) the cell has a diploid chromosome set (2c).
  • S the amount of DNA multiplied by replication.
  • G2M premitotic Phase
  • M short-term Mitosis phase it comes to the even distribution of reduplicated chromosomes on two daughter cells, each of which then returns a diploid DNA Show content and are in the G01 phase so that the cell cycle is new can start.
  • KB / HeLa cells were probed with the test substances in different concentrations (0.1-1000 nM) treated at 37 ° C for 24 hours.
  • the compounds 1, 2, 4 and 11 according to the invention have comparable activities like the reference compounds paclitaxel and mitoxantrone.
  • the core fragmentation is a late consequence of apoptotic processes.
  • the case too Observing changes can be attributed to endonucleases DNA strands and resulting fragmentation into nucleosomes particles traced.
  • Compounds 1 and 2 of the invention are characterized by improved water solubilities compared to compounds 10 and 14 .
  • Example 24 in vivo activity
  • Example 25 in vivo activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP04011598A 2003-06-05 2004-05-15 Derives d'indole destines a l'induction d'apoptose Withdrawn EP1595878A1 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
EP04011598A EP1595878A1 (fr) 2004-05-15 2004-05-15 Derives d'indole destines a l'induction d'apoptose
CA2526663A CA2526663C (fr) 2003-06-05 2004-05-25 Derives indoliques possedant une activite d'induction de l'apoptose
BRPI0410998-8A BRPI0410998A (pt) 2003-06-05 2004-05-25 derivados de indol com efeito de indução de apoptose
PCT/EP2004/005593 WO2004108702A1 (fr) 2003-06-05 2004-05-25 Derives indoliques possedant une activite d'induction de l'apoptose
YUP-2005/0901A RS20050901A (en) 2003-06-05 2004-05-25 Indole derivatives with apoptosis- inducing effect
MXPA05013121A MXPA05013121A (es) 2003-06-05 2004-05-25 Derivados de indol con efecto de induccion de apoptosis.
JP2006508197A JP4878285B2 (ja) 2003-06-05 2004-05-25 アポトーシス誘発作用を有するインドール誘導体
RU2006100022/04A RU2327696C2 (ru) 2003-06-05 2004-05-25 Производные индола, обладающие индуцирующим апоптоз эффектом (варианты), фармацевтическая композиция на их основе
EP04734662A EP1641777A1 (fr) 2003-06-05 2004-05-25 Derives indoliques possedant une activite d'induction de l'apoptose
KR1020057023347A KR101132599B1 (ko) 2003-06-05 2004-05-25 아폽토시스 유도 효과를 갖는 인돌 유도체
NZ543853A NZ543853A (en) 2003-06-05 2004-05-25 Indole derivatives with apoptosis-inducing effect
AU2004245198A AU2004245198B2 (en) 2003-06-05 2004-05-25 Indole derivatives with apoptosis-inducing effect
CN2004800192716A CN1816543B (zh) 2003-06-05 2004-05-25 具有细胞凋亡诱导效应的吲哚衍生物
TW093115555A TWI344462B (en) 2003-06-05 2004-05-31 Indole derivatives having an apoptosis-inducing effect
US10/858,751 US7205299B2 (en) 2003-06-05 2004-06-02 Indole derivatives having an apoptosis-inducing effect
ARP040101959A AR044628A1 (es) 2003-06-05 2004-06-04 Derivados de indol con accion inductora de la apoptosis
IL172130A IL172130A (en) 2003-06-05 2005-11-23 Indole derivatives with apoptosis-inducing effect and pharmaceutical compositions comprising same
NO20060045A NO20060045L (no) 2003-06-05 2006-01-04 Indolederivater med apoptoseinduserende effekt
HK06113749.1A HK1093065A1 (en) 2003-06-05 2006-12-14 Indole derivatives with apoptosis-inducing effect

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04011598A EP1595878A1 (fr) 2004-05-15 2004-05-15 Derives d'indole destines a l'induction d'apoptose

Publications (1)

Publication Number Publication Date
EP1595878A1 true EP1595878A1 (fr) 2005-11-16

Family

ID=34925013

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04011598A Withdrawn EP1595878A1 (fr) 2003-06-05 2004-05-15 Derives d'indole destines a l'induction d'apoptose

Country Status (1)

Country Link
EP (1) EP1595878A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001022954A2 (fr) * 1999-09-28 2001-04-05 Baxter Healthcare Sa Derives d"acide indolyl-3-glyoxyle a bonnes proprietes therapeutiques
WO2003022280A2 (fr) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 3-glyoxlylamide-indoles pour traitement du cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001022954A2 (fr) * 1999-09-28 2001-04-05 Baxter Healthcare Sa Derives d"acide indolyl-3-glyoxyle a bonnes proprietes therapeutiques
WO2003022280A2 (fr) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 3-glyoxlylamide-indoles pour traitement du cancer

Similar Documents

Publication Publication Date Title
DE69821633T2 (de) Heterozyklische verbindungen und antitumormittel, das diese als aktiven wirkstoff enthält
DE69427104T2 (de) Quinazoline Derivate und ihre Anwendung als Krebsmittel
DE60217322T2 (de) Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
EP1071420B1 (fr) Derives d'acide indolyl-3-glyoxylique a action antitumorale
DE60309913T2 (de) BICYCLISCHE BENZAMIDVERBINDUNGEN ALS FüR DIE BEHANDLUNG NEUROLOGISCHER KRANKHEITEN GEEIGNETE HISTAMIN-H3-REZEPTORLIGANDEN
DE60010448T2 (de) Amid-derivate
DE60022866T2 (de) Bizyklische heterozyklen, diese verbindungen enthaltende zusammenstellungen und verfahren zu deren herstellung
DE60315479T2 (de) Pyrimidinamid derivate und deren verwendung
HUE029370T2 (hu) Rákellenes aktivitású vegyületek
EP1280798A1 (fr) Heterocycles bicycliques, medicaments contenant ces composes, leur utilisation et leur procede de production
EP0624583A1 (fr) Mono- et bipyridylméthylpyridones substituées comme antagonistes d'angiotensine II
DE602004011515T2 (de) Furazanobenzimidazole
EP1599479A1 (fr) Imidazotriazines substituees
EP1240157B1 (fr) Derives substitues d'acide n-benzyl-indol-3-yl-glyoxalique a action antitumorale
EP1309585B1 (fr) Nouveaux derives d'indol et leur utilisation comme medicaments
US20040266762A1 (en) Indole derivatives having an apoptosis-inducing effect
EP1943220A2 (fr) Nouveaux beta antagonistes contenant de l'indole, procede de production associe et utilisation en tant que medicaments
EP1641777A1 (fr) Derives indoliques possedant une activite d'induction de l'apoptose
WO1988008842A2 (fr) 2-ACYLPYRIDIN-alpha-(N)-HETARYLHYDRAZONES SUBSTITUEES ET MEDICAMENTS CONTENANT CELLES-CI
DE69525633T2 (de) Chinoxalinderivate und ihre therapeutische verwendbarkeit
EP1467975A1 (fr) Alkyles uraciles substitues et leur utilisation
EP2029580B1 (fr) Nouveaux dérivés d'indole-pyrrole pour le traitement de maladies prolifératives et inflammatoires
DD293349A5 (de) Verfahren zur herstellung neuer thiouracilderivate und ihrer saeureadditionssalze
EP1595878A1 (fr) Derives d'indole destines a l'induction d'apoptose
EP1484329A1 (fr) Dérivés d'indole déstinés à l'induction d'apoptose

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20051213